AC
FLXN

Armistice Capital’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Armistice Capital’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-400,000
Closed -$4.53M – 94
2018
Q4 		$4.53M Buy
+400,000
New +$6.27M 0.34% 51

Other funds holding FLXN

MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Armistice Capital's FLXN Position: Q1 2019 in Review

Armistice Capital sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2019, closing a stake of 400,000 shares — an estimated $4.53M sold.

Armistice Capital first reported a position in FLXN in Q4 2018 and held it in 1 quarter. The position peaked at $4.53M in Q4 2018. 129 funds tracked by Wall St. Rank hold FLXN as of Q1 2019.

  • Armistice Capital reported no remaining Flexion Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Armistice Capital sold 400,000 Flexion Therapeutics, Inc. shares in Q1 2019, an estimated $4.53M.
  • Armistice Capital first reported a position in Flexion Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Armistice Capital's Flexion Therapeutics, Inc. position peaked at $4.53M in Q4 2018.
  • 129 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.